CAPTRUST FINANCIAL ADVISORS - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.

Quarter-by-quarter ownership
CAPTRUST FINANCIAL ADVISORS ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$1,080,782
-20.6%
25,809
+6.5%
0.00%
-20.0%
Q2 2023$1,360,665
+15.9%
24,237
-6.6%
0.01%0.0%
Q1 2023$1,173,997
+10.2%
25,956
-1.0%
0.01%0.0%
Q4 2022$1,065,502
-36.1%
26,212
+2.7%
0.01%
-50.0%
Q3 2022$1,667,000
+15.4%
25,511
+7.3%
0.01%
+11.1%
Q2 2022$1,445,000
+9.7%
23,784
+13.3%
0.01%0.0%
Q1 2022$1,317,000
-30.4%
20,984
-16.0%
0.01%
-30.8%
Q4 2021$1,893,000
-3.2%
24,984
+43.0%
0.01%
-18.8%
Q3 2021$1,955,000
-43.1%
17,466
-17.8%
0.02%
-50.0%
Q2 2021$3,438,000
+27.9%
21,239
-3.7%
0.03%
+10.3%
Q1 2021$2,687,000
+1.7%
22,050
+27.8%
0.03%
-17.1%
Q4 2020$2,642,000
+81.3%
17,253
-1.3%
0.04%
+45.8%
Q3 2020$1,457,000
-3.4%
17,478
-9.1%
0.02%
-4.0%
Q2 2020$1,509,000
+111.6%
19,225
+3.8%
0.02%
+56.2%
Q1 2020$713,000
-18.4%
18,514
+25.6%
0.02%
+14.3%
Q4 2019$874,000
+2031.7%
14,739
+1373.9%
0.01%
+1300.0%
Q3 2019$41,000
-12.8%
1,0000.0%0.00%
-50.0%
Q2 2019$47,000
+30.6%
1,0000.0%0.00%
+100.0%
Q1 2019$36,000
+620.0%
1,000
+1134.6%
0.00%
Q2 2018$5,000810.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q3 2023
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$31,294,00031.24%
NEA Management Company, LLC 1,590,002$365,593,00010.56%
Ariose Capital Management Ltd 37,900$2,379,0009.30%
ARK Investment Management 9,404,071$590,294,0002.46%
NIA IMPACT ADVISORS, LLC 80,082$5,027,0002.44%
Nikko Asset Management Americas, Inc. 4,619,747$291,044,0002.14%
PLUSTICK MANAGEMENT LLC 50,000$3,139,0001.98%
Integral Health Asset Management, LLC 120,000$7,532,0001.96%
Valiant Capital Management, L.P. 240,683$15,108,0001.73%
Deuterium Capital Management, LLC 18,000$1,130,0001.45%
View complete list of CRISPR THERAPEUTICS AG shareholders